Patents by Inventor Dae Wook Kang
Dae Wook Kang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240145346Abstract: A semiconductor device includes a substrate with a conductive pattern. A semiconductor die is electrically connected to the substrate and both the semiconductor die and the substrate are at least partially covered by a package body. In some examples, through-mold vias are formed in the package body to provide electrical signal paths from an exterior surface thereof to the conductive pattern of the substrate. In some examples, through-mold vias are included in the package body to provide electrical signal paths between the semiconductor die and an exterior surface of the package body. In some examples, an interposer is electrically connected to the through-mold vias and may be covered by the package body and/or disposed in spaced relation thereto. In some examples, the interposer may not be electrically connected to the through-mold vias but may have one or more semiconductor dies of the semiconductor device electrically connected thereto.Type: ApplicationFiled: January 8, 2024Publication date: May 2, 2024Applicant: Amkor Technology Singapore Holding Pte. LtdInventors: Dong Joo PARK, Jin Seong KIM, Ki Wook LEE, Dae Byoung KANG, Ho CHOI, Kwang Ho KIM, Jae Dong KIM, Yeon Soo JUNG, Sung Hwan CHO
-
Publication number: 20240137255Abstract: A method of transmitting a Physical Layer Convergence Procedure (PLCP) frame in a Very High Throughput (VHT) Wireless Local Area Network (WLAN) system includes generating a MAC Protocol Data Unit (MPDU) to be transmitted to a destination station (STA), generating a PLCP Protocol Data Unit (PPDU) by adding a PLCP header, including an L-SIG field containing control information for a legacy STA and a VHT-SIG field containing control information for a VHT STA, to the MPDU, and transmitting the PPDU to the destination STA. A constellation applied to some of Orthogonal Frequency Division Multiplex (OFDM) symbols of the VHT-SIG field is obtained by rotating a constellation applied to an OFDM symbol of the L-SIGfield.Type: ApplicationFiled: January 5, 2024Publication date: April 25, 2024Inventors: Dae Won Lee, Dong Wook Roh, Byeong Woo Kang, Yong Ho Seok, Yu Jin Noh, Bong Hoe Kim
-
Publication number: 20230220494Abstract: The present disclosure provides for characterization of normal flora and identifying biomarkers in the gut of healthy, neurotypical subjects. Aspect of the disclosure provide for the characterization of the gut microbiome in ADS subjects, characterized by reduced richness and significant loss of the ‘Prevotella-like enterotype’ compared to neurotypical subjects. The relative abundance of genera Prevotella, Coprococcus, Prevotellaceae and Veillonellaceae are significantly lower in autistic children than in neurotypical children. Further, Prevotella, is one of the three main classifiers for the human enterotypes, along with Bacteroides and Ruminococcus. These three core genera are among main contributors in the principle component analysis. ‘Prevotella-like enterotype’ was absent in the autistic group, while neurotypical samples showed an even distribution among the three enterotypes.Type: ApplicationFiled: December 28, 2022Publication date: July 13, 2023Inventors: Rosa Krajmalnik-Brown, Dae-Wook Kang, Jin Gyoon Park, Joshua Labaer, Zehra IIhan
-
Patent number: 11542560Abstract: The present disclosure provides for characterization of normal flora and identifying biomarkers in the gut of healthy, neurotypical subjects. Aspect of the disclosure provide for the characterization of the gut microbiome in ADS subjects, characterized by reduced richness and significant loss of the ‘Prevotella-like enterotype’ compared to neurotypical subjects. The relative abundance of genera Prevotella, Coprococcus, Prevotellaceae and Veillonellaceae are significantly lower in autistic children than in neurotypical children. Further, Prevotella, is one of the three main classifiers for the human enterotypes, along with Bacteriodes and Ruminococcus. These three core genera are among main contributors in the principle component analysis. ‘Prevotella-like enterotype’ was absent in the autistic group, while neurotypical samples showed an even distribution among the three enterotypes.Type: GrantFiled: August 30, 2018Date of Patent: January 3, 2023Assignee: Board of Regents on Behalf of Arizona State UniversityInventors: Rosa Krajmalnik-Brown, Dae-Wook Kang, Jin Gyoon Park, Joshua Labaer, Zehra Ilhan
-
Patent number: 11357801Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for modulating the abundance of one or more gut microorganisms in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a fecal microbe preparation to achieve at least a 2-fold change of the abundance of said one or more fecal microorganisms, wherein said one or more gut microorganisms are selected from the group consisting of Bifidobacterium, Prevotella, Desulfovibrio, Copprococcus, Clostridium, and Bacteroides.Type: GrantFiled: June 14, 2017Date of Patent: June 14, 2022Assignee: Arizona Board of Regents on Behalf of Arizona State UniversityInventors: James Adams, Dae-Wook Kang, Rosa Krajmalnik-Brown
-
Publication number: 20220163538Abstract: Provided herein are metabolites and methods of using the metabolites for diagnosing and treating Autism Spectrum Disorder (ASD) in a subject with a gastrointestinal problem, for determining a personalized treatment protocol for the subject, and for monitoring the therapeutic effect of an ASD treatment protocol in the subject being treated with the ASD treatment protocol.Type: ApplicationFiled: April 6, 2020Publication date: May 26, 2022Inventors: JAMES B. ADAMS, JUERGEN HAHN, DAE-WOOK KANG, ROSA KRAJMALNIK-BROWN
-
Publication number: 20220088089Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.Type: ApplicationFiled: December 1, 2021Publication date: March 24, 2022Applicants: Arizona Board Regents on behalf of Arizona State University, Regents of the University of Minnesota, Finch Therapeutics Holdings LLCInventors: James ADAMS, Rosa KRAJMALNIK-BROWN, Dae-Wook KANG, Michael J. SADOWSKY, Alexander KHORUTS, Thomas J. BORODY
-
Patent number: 11202808Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.Type: GrantFiled: December 28, 2018Date of Patent: December 21, 2021Assignees: Arizona Board of Regents on Behalf of Arizona State University, Regents of The University of Minnesota, Finch Therapeutics Holdings LLCInventors: James Adams, Rosa Krajmalnik-Brown, Dae-Wook Kang, Michael J. Sadowsky, Alexander Khoruts, Thomas J. Borody
-
Publication number: 20200061127Abstract: The present disclosure relates to methods and compositions suitable for changing metabolite levels in a subject in need thereof. In particular, this application provides methods and compositions for changing metabolite levels in a subject diagnosed with Autism Spectrum Disorder (ASD). Methods of preventing or treating an ASD in a subject thereof, as well as methods of selecting a treatment plan for treating an ASD in a subject are also provided.Type: ApplicationFiled: November 10, 2017Publication date: February 27, 2020Applicant: Arizona Board of Regents on behalf of Arizona State UniversityInventors: James ADAMS, Dae-Wook KANG, Rosa KRAJMALNIK-BROWN
-
Publication number: 20200061148Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.Type: ApplicationFiled: August 22, 2019Publication date: February 27, 2020Applicants: Arizona Board of Regents on behalf of Arizona State University, Regents of the University of Minnesota, Crestovo Holdings LLCInventors: James ADAMS, Rosa KRAJMALNIK-BROWN, Dae-Wook KANG, Michael J. SADOWSKY, Alexander KHORUTS, Thomas J. BORODY
-
Publication number: 20190358274Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.Type: ApplicationFiled: May 24, 2019Publication date: November 28, 2019Inventors: James ADAMS, Rosa KRAJMALNIK-BROWN, Dae-Wook KANG
-
Publication number: 20190328825Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.Type: ApplicationFiled: July 12, 2019Publication date: October 31, 2019Applicants: Arizona Board of Regents on behalf of Arizona State University, Regents of the University of Minnesota, Crestovo Holdings LLCInventors: James ADAMS, Rosa KRAJMALNIK-BROWN, Dae-Wook KANG, Michael J. SADOWSKY, Alexander KHORUTS, Thomas J. BORODY
-
Publication number: 20190144923Abstract: The present disclosure provides for characterization of normal flora and identifying biomarkers in the gut of healthy, neurotypical subjects. Aspect of the disclosure provide for the characterization of the gut microbiome in ADS subjects, characterized by reduced richness and significant loss of the ‘Prevotella-like enterotype’ compared to neurotypical subjects. The relative abundance of genera Prevotella, Coprococcus, Prevotellaceae and Veillonellaceae are significantly lower in autistic children than in neurotypical children. Further, Prevotella, is one of the three main classifiers for the human enterotypes, along with Bacteriodes and Ruminococcus. These three core genera are among main contributors in the principle component analysis. ‘Prevotella-like enterotype’ was absent in the autistic group, while neurotypical samples showed an even distribution among the three enterotypes.Type: ApplicationFiled: August 30, 2018Publication date: May 16, 2019Inventors: Rosa Krajmalnik-Brown, Dae-Wook Kang, Jin Gyoon Park, Joshua Labaer, Zehra IIhan
-
Publication number: 20190134144Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.Type: ApplicationFiled: December 28, 2018Publication date: May 9, 2019Applicants: Arizona Board Regents on behalf of Arizona State University, Regents of the University of Minnesota, Crestovo Holdings LLCInventors: James ADAMS, Rosa KRAJMALNIK-BROWN, Dae-Wook KANG, Michael J. SADOWSKY, Alexander KHORUTS, Thomas J. BORODY
-
Publication number: 20190134111Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for modulating the abundance of one or more gut microorganisms in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a fecal microbe preparation to achieve at least a 2-fold change of the abundance of said one or more fecal microorganisms, wherein said one or more gut microorganisms are selected from the group consisting of Bifidobacterium, Prevotella, Desulfovibrio, Copprococcus, Clostridium, and Bacteroides.Type: ApplicationFiled: June 14, 2017Publication date: May 9, 2019Inventors: James ADAMS, Dae-Wook KANG, Rosa KRAJMALNIK-BROWN
-
Publication number: 20170360848Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for modulating the abundance of one or more gut microorganisms in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising a fecal microbe preparation to achieve at least a 2-fold change of the abundance of said one or more gut microorganisms, wherein said one or more gut microorganisms are selected from the group consisting of Bifidobacterium, Prevotella, Desulfovibrio, Copprococcus, Clostridium, and Bacteroides.Type: ApplicationFiled: October 11, 2016Publication date: December 21, 2017Inventors: James ADAMS, Dae-Wook KANG, Rosa KRAJMALNIK-BROWN
-
Publication number: 20170356029Abstract: The present disclosure provides for characterization of normal flora and identifying biomarkers in the gut of healthy, neurotypical subjects. Aspect of the disclosure provide for the characterization of the gut microbiome in ADS subjects, characterized by reduced richness and significant loss of the ‘Prevotella-like enterotype’ compared to neurotypical subjects. The relative abundance of genera Prevotella, Coprococcus, Prevotellaceae and Veillonellaceae are significantly lower in autistic children than in neurotypical children. Further, Prevotella, is one of the three main classifiers for the human enterotypes, along with Bacteroides and Ruminococcus. These three core genera are among main contributors in the principle component analysis. ‘Prevotella-like enterotype’ was absent in the autistic group, while neurotypical samples showed an even distribution among the three enterotypes.Type: ApplicationFiled: June 22, 2017Publication date: December 14, 2017Inventors: Rosa Krajmalnik-Brown, Dae-Wook Kang, Jin Gyoon Park, Joshua Labaer, Zehra Ilhan
-
Patent number: 9719144Abstract: The present disclosure provides for characterization of normal flora and identifying biomarkers in the gut of healthy, neruotypical subjects. Aspect of the disclosure provide for the characterization of the gut microbiome in ADS subjects, characterized by reduced richness and significant loss of the ‘Prevotella-like enterotype’ compared to neurotypical subjects. The relative abundance of genera Prevotella, Coprococcus, Prevotellaceae and Veillonellaceae are significantly lower in autistic children than in neurotypical children. Further, Prevotella, is one of the three main classifiers for the human enterotypes, along with Bacteroides and Ruminococcus. These three core genera are among main contributors in the principle component analysis. ‘Prevotella-like enterotype’ was absent in the autistic group, while neurotypical samples showed an even distribution among the three enterotypes.Type: GrantFiled: March 15, 2013Date of Patent: August 1, 2017Assignee: ARIZONA BOARD OF REGENTSInventors: Rosa Krajmalnik-Brown, Dae-Wook Kang, Jin Gyoon Park, Joshua Labaer, Zehra Ilhan
-
Publication number: 20160339065Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.Type: ApplicationFiled: May 23, 2016Publication date: November 24, 2016Applicants: Arizona Board of Regents on Behalf of Arizona State University, Regents of the University of Minnesota, Crestovo LLCInventors: James ADAMS, Rosa KRAJMALIK-BROWN, Dae-Wook KANG, Michael J. SADOWSKY, Alexander KHORUTS, Thomas J. BORODY
-
Patent number: 9444322Abstract: Provided is a method for suppressing a circulating current in a modular multi-level converter for a high voltage direction-current (HVDC) transmission system. The HVDC transmission system converts an alternating current (AC) into a direct current (DC) and vice versa, transmits energy using a DC cable, and including a modular multilevel converter generating a high voltage source by stacking a plurality of sub-modules in series. In the circulating current suppression method, a circulating current (idiffj; j=a,b,c) of a,b,c phase in an abc 3-phase stationary reference frame, a DC current (idc) flowing in a DC cable, a current reference value (i*dc) of a DC component that needs to flow in the DC cable are inputted. The circulating current (idiffj) of the a,b,c phase is controlled to become zero. A compensation value (V*diffj) for suppressing a harmonic component of the circulating current is outputted.Type: GrantFiled: October 25, 2013Date of Patent: September 13, 2016Assignee: Korea Electrotechnology Research InstituteInventors: Jung Woo Park, Dae Wook Kang, Jong Hyun Kim, Dong Wook Yoo, Ji Woo Moon, Jin Soo Kwon, Chun Sung Kim, Deuk Woo Bae